Study links DHA with diabetic retinopathy
Diabetic retinopathy, or DR, is a leading cause of blindness that occurs when blood sugar blocks the tiny vessels that supply blood to the retina. Researchers know that docosahexaenoic acid, or DHA, an omega-3 fatty acid found in the eyes in high concentration, supports eye and vision health, but do not yet fully understand its relation to DR.
In a recent functional study, researchers at the University of Illinois at Chicago examined the correlation between DHA levels and the development of diabetic retinopathy. Sugasini Dhavamani, a research assistant professor, and Poorna Chandra Rao Yalgala, a researcher, led the study.
“We showed for the first time that reduced retinal DHA levels in humans and mice models of diabetes,” Dhavamani said.
The team determined DHA levels, activity and function in the retina using gas chromatography–mass spectrometry, optical coherence tomography and electroretinography, respectively. They found that DHA levels in mice that were genetically modified to have diabetes were 9% to 11% and in diabetic humans were 8% to 10%, whereas DHA levels of nondiabetic mice and humans were 15% to 18%, meaning they observed a 40% to 50% reduction of DHA in diabetic mice and humans.
The observed difference correlated with variations in the levels of fatty acid elongation, metabolism and inflammation markers. The researchers also reported reduced retinal thickness and function in diabetic mice and humans.
While oily fish is a major dietary source of DHA, clinical trials with fish oil have not improved visual function. “This is due to the specificity of blood–retinal barrier that is incompatible with the specificity of the intestinal barrier,” Dhavamani said.
The researchers previously tested whether this limitation could be overcome using a lysophospholipid form of DHA to improve retinal function. They found that it is possible to increase retinal DHA by almost 100% in a normal adult mouse with a low dose of lysophosphatidylcholine-DHA.
The UIC team believes this form of DHA could be used therapeutically to prevent or mitigate retinal dysfunction associated with diabetes and Alzheimer’s disease, as well as age-related macular degeneration. Moreover, it could pave the way for a safe, cost-effective nutraceutical strategy to prevent diabetes-associated visual sensitivity decline in a majority of the population.
Details
Sugasini Dhavamani will present this research from 4:30 to 5:30 p.m. CDT on March 25, at Discover BMB 2024, the American Society for Biochemistry and Molecular Biology annual meeting in San Antonio. Her poster is at Board 191.
Abstract title: DHA deficiency linked to diabetic retinopathy progression in experimental animal models and patients with diabetic mellitus — a novel finding.
Enjoy reading ASBMB Today?
Become a member to receive the print edition monthly and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
The quest to treat and cure xerostomia
Blake Warner, chief of the Salivary Disorders Unit at the NIH talks about his lab’s efforts to develop treatments for dry mouth.
There's more to blue cheese than just the stench
Virginia Tech researchers discovered a way to synthesize a compound in the mold of blue cheese that has antibacterial and anticancer properties.
Engineering cells to broadcast their behavior can help scientists study their inner workings
Researchers can use waves to transmit signals from the invisible processes and dynamics underlying how cells make decisions.
From the journals: JBC
Lung cancer cells resist ferroptosis. ORMDL3 in ulcerative colitis. Novel genetic variants in thyroid cancer. Read about these recent papers.
Seeking the sweet spot to beat a pig parasite
Researchers extracted, separated and tested glycans from the porcine whipworm in an effort to determine the best way to develop treatments and vaccines.
Radioactive drugs strike cancer with precision
The tumor-seeking radiopharmaceuticals are charting a new course in oncology, with promise for targeted treatments with fewer side effects.